ReviewCureus2025
Comparative Efficacy and Safety of Antibody-Drug Conjugates Versus Standard Chemotherapy in Metastatic Breast Cancer: A Comprehensive Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) represent a novel class of therapeutics that link monoclonal antibodies to potent cytotoxic drugs, enabling targeted delivery and reduced systemic toxicity compared with conventional chemotherapy. In metastatic breast cancer (MBC), ADCs have emerged as an important treatment option across human epidermal growth factor receptor 2 (HER2)-positive, HER2-low, and triple-negative subtypes. This systematic review and meta-analysis evaluated the efficacy and safety of ADCs compared with standard chemotherapy by analyzing data from nine randomized controlled trials including 3,498 patients. The pooled results demonstrated that ADCs significantly improved overall survival (OS) and objective response rates while maintaining comparable progression-free survival and showing no increase in grade 3 or higher adverse events. Heterogeneity was low for OS but higher for response rates, reflecting variability among drug types and patient populations. Safety analyses showed that ADCs were generally well tolerated, with fewer severe hematologic and gastrointestinal toxicities than chemotherapy, although specific toxicities such as interstitial lung disease with trastuzumab deruxtecan require ongoing monitoring. Overall, the evidence confirms that ADCs provide superior therapeutic benefits and better tolerability than conventional chemotherapy in MBC, marking a significant advance toward more precise and effective systemic treatment strategies that improve survival and quality of life for patients with advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.